Clinical Trials Logo
  1. Home
  2. Hemochromatosis
  3. NCT00199628
  4. Details
NCT00199628 Clinical Trial

Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization

Hemochromatosis Clinical Trial

Official title:
Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00199628
Other study ID # I05001
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 2005
Est. completion date August 2014

Study information
Verified date September 2005
Source University Hospital, Limoges
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Problems of compatibility between a mother and her child are frequent. The most well-known case can be illustrated by the fetomaternal blood group incompatibility (rhesus factor) which can induce severe anemia of the fetus.

The investigators recently proved that incompatibility between mother and child can concern an organ leading to a tissular alloimmunization. For example, neonatal membranous glomerulonephritis (a kidney disease) can result from this mechanism.

The purpose of this network is to detect and study neonatal diseases induced by tissular fetomaternal alloimmunization. The detection of these diseases will be performed by the mother's serum analysis.

Recruitment information / eligibility
Status Completed
Enrollment 100
Est. completion date August 2014
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

Mothers having a child suffering from:

- Neonatal membranous glomerulonephritis

- Unexplained neonatal tubular defect

- Unexplained thrombotic microangiopathy

- Neonatal hemochromatosis

Exclusion Criteria:

- Any cause explaining the child's disease

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Limoges University Hospital Limoges

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Limoges

Country where clinical trial is conducted

France, 

See also
  Status Clinical Trial Phase
Completed NCT03654794 - Study of the Cellular Diffusion of Tacrolimus Across the Membrane of Mononuclear Cells
Terminated NCT00122980 - Stroke With Transfusions Changing to Hydroxyurea Phase 3
Completed NCT00202436 - Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy Phase 3
Withdrawn NCT01892644 - Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome Phase 2
Not yet recruiting NCT01524757 - Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis N/A
Completed NCT00349453 - Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients Phase 2
Recruiting NCT03743272 - Repeatability and Reproducibility of Multiparametric MRI
Recruiting NCT06137079 - "Iron Overload and Endocrinological Diseases"
Completed NCT00712738 - Oral Nifedipine to Treat Iron Overload Phase 1
Completed NCT00001455 - Iron Overload in African Americans N/A
Completed NCT00006312 - Hemochromatosis--Genetic Prevalence and Penetrance N/A
Completed NCT00005559 - Statistical Basis for Hemochromatosis Screening N/A
Recruiting NCT00509652 - Erythrocyte Apheresis Versus Phlebotomy in Hemochromatosis N/A
Completed NCT00350662 - Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients Phase 3
Completed NCT00005541 - Hemochromatosis and Iron Overload Screening Study (HEIRS) N/A
Completed NCT00000595 - Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis Phase 2
Recruiting NCT04631718 - MRI QSM Imaging for Iron Overload
Active, not recruiting NCT00007150 - Treatment of Hemochromatosis Phase 2
Completed NCT00587535 - Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration N/A
Enrolling by invitation NCT02025543 - Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content